MDXH - MDxHealth SA Price to Earnings Adjusted for Growth Rate

MDxHealth SA is expanding its network of urological clinics through genetics partnerships. The company achieves cost optimization via outsourced logistics management and cloud IT services. The GURU.Markets terminal displays a chart of the P/E ratio relative to growth, where 0.00 determines the current status of the parameter. High demand for ConfirmMDx tests is creating positive momentum, as the market has already priced in their development costs.

MDxHealth Inc. (MDXH): PEG Multiple from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for MDxHealth SA (MDXH)

- current price and projected stock value:

Price Chart MDxHealth S.A.|MDXH - Consensus Target

- market capitalization statistics:

Market Value MDxHealth Inc.|MDXH - Total Company Value

- shareholders' equity book value data:

Net Assets per Share MDxHealth SA|MDXH - Book Capitalization|Market Capitalization to Book Value mdxhealth.com|MDXH - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

MDXH - Net Profit|Expected Net Profit MDxHealth SA|MDXH - P/E Multiple|Forward P/E Multiple MDxHealth, Inc.|MDXH - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MDxHealth Inc.|MDXH - Operating profit before deduction of amortization|Earnings per share for the last four quarters MDxHealth SA|MDXH - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months mdxhealth.com|MDXH - Net earnings per share growth this year|Expected earnings per share trend next year MDxHealth SA

General company analysis:MDxHealth S.A. (MDXH)

The expansion of MDxHealth (MDXH) molecular tests within US urology defines the profit potential, which this indicator compares with the current P/E to value growth rates. This calculation reveals an undervalued asset when the value is below one, allowing the normalized PEG ratio to determine the efficiency of discounting future cash flows relative to market capitalization.

Who MDxHealth SA competes with